Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DAZ-associated protein 2 (DAZAP2) is a small (~17 kDa) proline-rich adaptor protein encoded by the DAZAP2 gene on chromosome 12, structurally characterized by a central proline-rich region and SH2/SH3 binding sites[3]. The protein is expressed ubiquitously, with notable function in the cytoplasm and nucleus. DAZAP2 interacts with deleted in azoospermia (DAZ), SARA (Smad anchor for receptor activation), eukaryotic initiation factor 4G, and the E3 ubiquitin ligase SIAH1. It regulates the stability of key signaling proteins (notably the kinase HIPK2), modulates the p53 pathway response to DNA damage, affects stress granule formation, RNA splicing, and is implicated in spermatogenesis[1][2][3][5]. Downregulation of DAZAP2 has been linked to multiple myeloma, and recent research indicates it acts as a pan-coronavirus restriction factor inhibiting viral RNA replication[4]. DAZAP2 is not classified as a classical drug target (such as a receptor or enzyme), but rather as an adaptor protein in key cellular pathways.
No drugs act on DAZAP2 directly; any mechanisms would be indirect via pathways it regulates.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DAZ-associated protein 2 (DAZAP2).